|
1
|
DeSantis CE, Miller KD, Dale W, Mohile SG,
Cohen HJ, Leach CR, Goding Sauer A, Jemal A and Siegel RL: Cancer
statistics for adults aged 85 years and older, 2019. CA Cancer J
Clin. 69:452–467. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barry MJ and Simmons LH: Prevention of
Prostate Cancer Morbidity and Mortality: Primary Prevention and
Early Detection. Med Clin North Am. 101:787–806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rigau M, Olivan M, Garcia M, Sequeiros T,
Montes M, Colás E, Llauradó M, Planas J, Torres Id, Morote J, et
al: The present and future of prostate cancer urine biomarkers. Int
J Mol Sci. 14:12620–12649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
López Estebaránz JL, Zarco-Montejo P,
Samaniego ML and García-Calvo C; PREVAL Study Group, : Prevalence
and clinical features of psoriatic arthritis in psoriasis patients
in Spain. Limitations of PASE as a screening tool. Eur J Dermatol.
25:57–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Streicher J, Meyerson BL, Karivedu V and
Sidana A: A review of optimal prostate biopsy: Indications and
techniques. Ther Adv Urol. 11:1756287219870074. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kopp RP, Parsons JK, Shiau J,
Wang-Rodriguez J, Palazzi-Churas K, Silberstein JL, Derweesh IH and
Sakamoto K: Prostate atypia: Clinical and pathological variables
associated with cancer diagnosis on repeat biopsy. Prostate Cancer
Prostatic Dis. 14:149–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Varma M and Jasani B: Diagnostic utility
of immunohistochemistry in morphologically difficult prostate
cancer: Review of current literature. Histopathology. 47:1–16.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan P, Wang S, Sun X, Xu H, Ye Z and Chen
Z: Quality of life among patients after cystoprostatectomy as the
treatment for locally advanced prostate cancer with bladder
invasion. Aging Male. 1–7. 2019.[Epub ahead of print]. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prcic A, Begic E and Hiros M: Actual
contribution of free to total PSA ratio in prostate diseases
differentiation. Med Arch. 70:288–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carter HB: Prostate-Specific antigen (PSA)
screening for prostate cancer: Revisiting the evidence. JAMA.
319:1866–1868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paiva RM, Zauli DAG, Neto BS and Brum IS:
Urinary microRNAs expression in prostate cancer diagnosis: A
systematic review. Clin Transl Oncol. 2020.[Epub ahead of print].
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang Z, Woda BA, Rock KL, Xu Y, Savas L,
Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, et al: P504S: A
new molecular marker for the detection of prostate carcinoma. Am J
Surg Pathol. 25:1397–1404. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jain D, Gupta S, Marwah N, Kalra R, Gupta
V, Gill M, Jain N, Lal S and Sen R: Evaluation of role of
alpha-methyl acyl-coenzyme A racemase/P504S and high molecular
weight cytokeratin in diagnosing prostatic lesions. J Cancer Res
Ther. 13:21–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee CO, Lee KW, Kim DS, Jeon YS and Lee
NK: The usefulness of P504S/34βE12 immunostaining for the detection
of prostate cancer. J Urol. 181:802. 2007. View Article : Google Scholar
|
|
17
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
international society of urological pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016.PubMed/NCBI
|
|
18
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérez-Ibave DC, Burciaga-Flores CH and
Elizondo-Riojas MÁ: Prostate-specific antigen (PSA) as a possible
biomarker in non-prostatic cancer: A review. Cancer Epidemiol.
54:48–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loeb S, Vellekoop A, Ahmed HU, Catto J,
Emberton M, Nam R, Rosario DJ, Scattoni V and Lotan Y: Systematic
review of complications of prostate biopsy. Eur Urol. 64:876–892.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Kafaji G, Said HM, Alam MA and Al Naieb
ZT: Blood-based microRNAs as diagnostic biomarkers to discriminate
localized prostate cancer from benign prostatic hyperplasia and
allow cancer-risk stratification. Oncol Lett. 16:1357–1365.
2018.PubMed/NCBI
|
|
22
|
Claessens M, Van Poppel H, Goike H and
Joniau S: POD4.01: Role of TPS, TPA and PSA in treatment monitoring
of prostate carcinoma. Urology. 72:S402008. View Article : Google Scholar
|
|
23
|
Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu
PG, Tretiakova MS, Young RH, Weiss LM, Blute RD Jr, Brendler CB, et
al: Alpha-methylacyl-CoA racemase: A multi-institutional study of a
new prostate cancer marker. Histopathology. 45:218–225. 2010.
View Article : Google Scholar
|
|
24
|
Kahane H and Bostwick DG: Florid basal
cell hyperplasia and other benign mimics of prostate cancer.
Pathology Case Reviews. 19:154–162. 2014. View Article : Google Scholar
|
|
25
|
Skinnider BF, Oliva E, Young RH and Amin
MB: Expression of alpha-methylacyl-CoA racemase (P504S) in
nephrogenic adenoma: A significant immunohistochemical pitfall
compounding the differential diagnosis with prostatic
adenocarcinoma. Am J Surg Pathol. 28:701–705. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Allan CH and Epstein JI: Nephrogenic
adenoma of the prostatic urethra: A mimicker of prostate
adenocarcinoma. Am J Surg Pathol. 25:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rathod SG, Jaiswal DG and Bindu RS:
Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain
in prostate neoplasm. J Family Med Prim Care. 28:2651–2655.
2019.
|
|
28
|
Abdollah F, Dalela D, Haffner MC, Culig Z
and Schalken J: The role of biomarkers and genetics in the
diagnosis of prostate cancer. Eur Urol Focus. 1:99–108. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guelfi G, Cochetti G, Stefanetti V,
Zampini D, Diverio S, Boni A and Mearini E: Next generation
sequencing of urine exfoliated cells: An approach of prostate
cancer microRNAs research. Sci Rep. 8:7112018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Egidi MG, Cochetti G, Serva MR, Guelfi G,
Zampini D, Mechelli L and Mearini E: Circulating microRNAs and
kallikreins before and after radical prostatectomy: Are they really
prostate cancer markers? Biomed Res Int. 2013:2417802013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cochetti G, Poli G, Guelfi G, Boni A,
Egidi MG and Mearini E: Different levels of serum microRNAs in
prostate cancer and benign prostatic hyperplasia: Evaluation of
potential diagnostic and prognostic role. Onco Targets Ther.
9:7545–7553. 2016. View Article : Google Scholar : PubMed/NCBI
|
